The FY2023 (Dec) proxy of IDEAYA Biosciences names 21 peer companies for pay. Pay versus performance data of IDEAYA Biosciences for that year is not on file, so it has no rank.
Pay peer group, FY2023 (Dec) proxy
| ALX Oncology Holdings, Inc. | Not disclosed | Not disclosed |
| C4 Therapeutics, Inc. | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Erasca, Inc. | Not disclosed | Not disclosed |
| Gossamer Bio, Inc. | Not disclosed | Not disclosed |
| Imago BioSciences, Inc. | Not disclosed | Not disclosed |
| Inhibrx, Inc. | Not disclosed | Not disclosed |
| Iteos Therapeutics, Inc. | Not disclosed | Not disclosed |
| Jounce Therapeutics, Inc. | Not disclosed | Not disclosed |
| KalVista Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Kezar Life Sciences Inc. | Not disclosed | Not disclosed |
| Kura Oncology, Inc. | Not disclosed | Not disclosed |
| Mersana Therapeutics, Inc. | Not disclosed | Not disclosed |
| Nurix Therapeutics, Inc. | Not disclosed | Not disclosed |
| ORIC Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| PMV Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Precision BioSciences, Inc. | Not disclosed | Not disclosed |
| RAPT Therapeutics, Inc. | Not disclosed | Not disclosed |
| Replimune Group Inc. | Not disclosed | Not disclosed |
| Sutro Biopharma, Inc. | Not disclosed | Not disclosed |
| Zentalis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
21 companies
Changes by year
FY2025 (Dec) proxy
- AddedBiohavenpay peer groupCompanies added to the 2025 Peer Group based on alignment with the peer selection criteria: Biohaven, BridgeBio Pharma, CRISPR Therapeutics, Kymera Therapeutics, Protagonist Therapeutics
- AddedBridgeBio Pharmapay peer groupCompanies added to the 2025 Peer Group based on alignment with the peer selection criteria: Biohaven, BridgeBio Pharma, CRISPR Therapeutics, Kymera Therapeutics, Protagonist Therapeutics
- AddedCRISPR Therapeutics AGpay peer groupCompanies added to the 2025 Peer Group based on alignment with the peer selection criteria: Biohaven, BridgeBio Pharma, CRISPR Therapeutics, Kymera Therapeutics, Protagonist Therapeutics
- AddedKymera Therapeuticspay peer groupCompanies added to the 2025 Peer Group based on alignment with the peer selection criteria: Biohaven, BridgeBio Pharma, CRISPR Therapeutics, Kymera Therapeutics, Protagonist Therapeutics
- AddedProtagonist Therapeuticspay peer groupCompanies added to the 2025 Peer Group based on alignment with the peer selection criteria: Biohaven, BridgeBio Pharma, CRISPR Therapeutics, Kymera Therapeutics, Protagonist Therapeutics
- RemovedAmbrx Biopharmapay peer groupdue to acquisition or misalignment with the updated peer selection criteria: Ambrx Biopharma, Inhibrx Biosciences, RAPT Therapeutics, Replimune Group, Ventyx Biosciences, Zentalis Pharmaceuticals
- RemovedInhibrx Biosciencespay peer groupdue to acquisition or misalignment with the updated peer selection criteria: Ambrx Biopharma, Inhibrx Biosciences, RAPT Therapeutics, Replimune Group, Ventyx Biosciences, Zentalis Pharmaceuticals
- RemovedRAPT Therapeuticspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: Ambrx Biopharma, Inhibrx Biosciences, RAPT Therapeutics, Replimune Group, Ventyx Biosciences, Zentalis Pharmaceuticals
- RemovedReplimune Grouppay peer groupdue to acquisition or misalignment with the updated peer selection criteria: Ambrx Biopharma, Inhibrx Biosciences, RAPT Therapeutics, Replimune Group, Ventyx Biosciences, Zentalis Pharmaceuticals
- RemovedVentyx Biosciencespay peer groupdue to acquisition or misalignment with the updated peer selection criteria: Ambrx Biopharma, Inhibrx Biosciences, RAPT Therapeutics, Replimune Group, Ventyx Biosciences, Zentalis Pharmaceuticals
- RemovedZentalis Pharmaceuticalspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: Ambrx Biopharma, Inhibrx Biosciences, RAPT Therapeutics, Replimune Group, Ventyx Biosciences, Zentalis Pharmaceuticals
FY2024 (Dec) proxy
- AddedAmbrx Biopharmapay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedArcellxpay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedArvinaspay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedCelldex Therapeuticspay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedCervel Therapeuticspay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedCogent Biosciencespay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedDenali Therapeuticspay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedImmunovantpay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedMorphicpay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedNuvalentpay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedRelay Therapeuticspay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedRevolution Medicinespay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedSyndax Pharmaceuticalspay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- AddedXencorpay peer groupCompanies added to the 2024 Peer Group based on alignment with the peer selection criteria: Ambrx Biopharma, Arcellx, Arvinas, Celldex Therapeutics, Cogent Biosciences, Cervel Therapeutics, Denali Therapeutics, Immunovant, Morphic, Nuvalent, Relay Therapeutics, Revolution Medicines, Syndax Pharmaceuticals, Xencor, Vaxcyte, and Ventyx Biosciences
- RemovedALX Oncologypay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedC4 Therapeuticspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedErascapay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedGossamer Biopay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedImago Bio Sciencespay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedIteos Therapeuticspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedJounce Therapeuticspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedKalVista Pharmaceuticalspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedKezar Life Sciencespay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedMersana Therapeuticspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedNurix Therapeuticspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedORIC Pharmaceuticalspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedPMV Pharmaceuticalspay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedPrecision BioSciencespay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
- RemovedSutro Biopharmapay peer groupdue to acquisition or misalignment with the updated peer selection criteria: ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago Bio Sciences, Iteos Therapeutics, Jounce Therapeutics, KalVista Pharmaceuticals, Kezar Life Sciences, Mersana Therapeutics, Nurix Therapeutics, ORIC Pharmaceuticals, PMV Pharmaceuticals, Precision BioSciences
FY2023 (Dec) proxy
- AddedALX Oncologypay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- AddedC4 Therapeuticspay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- AddedErascapay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- AddedGossamer Biopay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- AddedImago BioSciencespay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- AddedIteos Therapeuticspay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- AddedMersana Therapeuticspay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- RemovedArcus Biosciencespay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- RemovedAtrecapay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- RemovedCue Biopharmapay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- RemovedHarpoon Therapeuticspay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- RemovedKaleido Biosciencespay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
- RemovedMustang Biopay peer groupChanges to the 2023 Peer Group from the prior year's peer group included the removal of one company, Kaleido Biosciences, which ceased operations in April 2022, and five companies, Arcus Biosciences, Atreca, Cue Biopharma, Harpoon Therapeutics, and Mustang Bio, which had market capitalization below or above our target market cap focus, and the inclusion of seven new companies, ALX Oncology, C4 Therapeutics, Erasca, Gossamer Bio, Imago BioSciences, Iteos Therapeutics, and Mersana Therapeutics, that were added to further expand the peer group with companies similar in size with a relevant industry focus
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.